These are the details of the phase II study that was announced earlier by Antibe. Very low levels of ulceration vs standard naproxen(ALEVE). Nothing unexpected and everything points towards what should be a successful phase III but you can never be sure with drug candidates.
Antibe has cash to complete their scheduled phase IIC trial for optimal dosage this winter. Should be completed by early 2019.
Still hunting for a big Daddy partner to fund phase III. Company estimated it could take up to a year to find the right partner.
Please post stock symbols first in all your posts. If it's a foreign stock, please list the US pk equivalent symbol.
If the Commodities Boom is Over, I am just a Gold Bug headed for the Windshield of LIFE
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.